Does Heavy Ion Therapy Work Through the Immune System?

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 5, 2016, Pages 934-936

  Durante, Marco ^a   Brenner, David J ^b   Formenti, Silvia C ^c  

^a UNIVERSITY OF TRENTO   (Italy)

^b NewYork Presbyterian Hospital   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HEAVY ION;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; HEAVY ION RADIATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOTHERAPY DOSAGE; ION THERAPY;

HEAVY ION RADIOTHERAPY; HEAVY IONS; HUMANS; IMMUNE SYSTEM;

EID: 85004025725     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.08.037     Document Type: Article

References (12)

1. 1 Gameiro, S.R., Malamas, A.S., Bernstein, M.B., et al. Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing. Int J Radiat Oncol Biol Phys 95 (2016), 120–130.
2. 2 Demaria, S., Golden, E.B., Formenti, S.C., Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1 (2015), 1325–1332.
3. 3 Crittenden, M., Kohrt, H., Levy, R., et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 25 (2015), 54–64.
4. 4 Golden, E.B., Formenti, S., Is tumor (R)ejection by the immune system the “5th R” of radiobiology?. Oncoimmunology, 3, 2014, e28133.
5. 5 Durante, M., Reppingen, N., Held, K.D., Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol Med 19 (2013), 565–582.
6. 6 Belyakov, O.V., Mitchell, S.A., Parikh, D., et al. Biological effects in unirradiated human tissue induced by radiation damage up to 1 mm away. Proc Natl Acad Sci U S A 102 (2005), 14203–14208.
7. 7 Loeffler, J.S., Durante, M., Charged particle therapy–optimization, challenges and future directions. Nat Rev Clin Oncol 10 (2013), 411–424.
8. 8 Shimokawa, T., Ma, L., Ando, K., et al. The future of combining carbon-ion radiotherapy with immunotherapy: Evidence and progress in mouse models. Int J Particle Ther, 2016, 10.14338/IJPT-15-00023.1.
9. 9 Kamada, T., Tsujii, H., Blakely, E.A., et al. Carbon ion radiotherapy in Japan: An assessment of 20 years of clinical experience. Lancet Oncol 16 (2015), e93–e100.
10. 10 Yovino, S., Kleinberg, L., Grossman, S.A., et al. The etiology of treatment-related lymphopenia in patients with malignant gliomas: Modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 31 (2013), 140–144.
11. 11 Durante, M., Yamada, S., Ando, K., et al. X-rays vs. carbon-ion tumor therapy: Cytogenetic damage in lymphocytes. Int J Radiat Oncol Biol Phys 47 (2000), 793–798.
12. 12 Pignalosa, D., Lee, R., Hartel, C., et al. Chromosome inversions in lymphocytes of prostate cancer patients treated with X-rays and carbon ions. Radiother Oncol 109 (2013), 256–261.